GTH Genetron Holdings Limited ADRs

Genetron Holdings, Ltd. engages in precision oncology. It provides cancer molecular profiling by using technologies in molecular biology and data science to transform cancer treatment. It products and services include diagnosis and monitoring through both LDT and IVD products. Its LDT portfolio consists of both specifically designed focused and comprehensive gene panel testing services. It also develops liver cancer early screening products. The company was founded by Si Zhen Wang, Hai Yan, and Wei Wu He in 2015 and is headquartered in Beijing, China. This is an ADR of a company that does not have its stock publicly traded anywhere else in the world.

$17.93  -0.84 (-4.48%)
As of 05/13/2021 15:59:46 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Small cap
GICS sector:  Health Care
Industry:  Diagnostics & Research
Index country:  China
Country of incorporation:  
IPO date:  06/19/2020
Outstanding shares:  88,871,720
Average volume:  302,345
Market cap:   $1,677,898,074
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
CUSIP:    37186H100
ISIN:        US37186H1005
Sedol:      BMX5PZ5
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.95
PS ratio:   25.36
Return on equity:   -181.33%
Net income %:   -723.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy